Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novocure Ltd Ord Sh (NVCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,314,140
  • Shares Outstanding, K 95,636
  • Annual Sales, $ 248,070 K
  • Annual Income, $ -63,560 K
  • 60-Month Beta 3.20
  • Price/Sales 17.34
  • Price/Cash Flow N/A
  • Price/Book 37.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.13
  • Number of Estimates 4
  • High Estimate -0.04
  • Low Estimate -0.27
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +43.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.51 +8.44%
on 04/17/19
49.12 -8.36%
on 04/03/19
-2.63 (-5.51%)
since 03/25/19
3-Month
41.51 +8.44%
on 04/17/19
56.67 -20.57%
on 03/04/19
-4.78 (-9.59%)
since 01/25/19
52-Week
23.61 +90.66%
on 04/26/18
56.67 -20.57%
on 03/04/19
+20.86 (+86.40%)
since 04/25/18

Most Recent Stories

More News
NVE Schedules Conference Call on Fourth-Quarter and Fiscal Year Results

NVE Corporation (Nasdaq:NVEC) announced that it plans to release its financial results for the quarter and fiscal year ended March 31, 2019 on Wednesday, May 1, 2019 after the close of the Nasdaq Regular...

NVEC : 97.20 (+0.30%)
NVCR : 44.56 (-1.22%)
Novocure Publishes 2018 Annual Report Featuring Company's Vision, Mission and Values

Novocure (NASDAQ: NVCR) announced today the publication of its 2018 Annual Report featuring its vision, mission and values, employee stories and videos, business highlights and selected financial...

NVCR : 44.56 (-1.22%)
Inaugural AACR-Novocure Tumor Treating Fields Research Grant Recipients Announced at AACR Annual Meeting 2019

The recipients of the AACR-Novocure Tumor Treating Fields research grants were announced on April 2 at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta....

NVCR : 44.56 (-1.22%)
Novocure to Report First Quarter 2019 Financial Results

Novocure (NASDAQ:NVCR) announced today that it will report financial results for the first quarter 2019 on Thursday, May 2, 2019, before the U.S. financial markets open. Novocure management...

NVCR : 44.56 (-1.22%)
Investor Expectations to Drive Momentum within Apple Hospitality REIT, Superior Energy Services, US Foods Holding, NovoCure, FTS International, and Envestnet -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Apple Hospitality REIT, Inc. (NYSE:APLE),...

SPN : 4.06 (-3.56%)
NVCR : 44.56 (-1.22%)
FTSI : 10.73 (+0.94%)
APLE : 16.31 (-0.85%)
USFD : 36.39 (+0.83%)
ENV : 71.30 (+0.85%)
Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer

--Ovarian cancer is the fifth leading cause of cancer death among women

NVCR : 44.56 (-1.22%)
Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019

--The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference

NVCR : 44.56 (-1.22%)
Novocure's Chief Science Officer Retires after 17 Years of Service

Novocure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure's Chief Science Officer and Head of Research and Development, effective May 1, 2019. Dr. Kirson will step...

NVCR : 44.56 (-1.22%)
Novocure to Participate in Oppenheimer's 29th Annual Healthcare Conference

Novocure (NASDAQ:NVCR) announced today that Wilco Groenhuysen, Novocure's Chief Financial Officer, will participate in Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019, in...

NVCR : 44.56 (-1.22%)
Interesting NVCR Put And Call Options For December 20th

Investors in NovoCure Ltd saw new options become available today, for the December 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value,...

NVCR : 44.56 (-1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators are in flux.

See More Share

Trade NVCR with:

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

2nd Resistance Point 46.46
1st Resistance Point 45.78
Last Price 44.56
1st Support Level 44.35
2nd Support Level 43.59

See More

52-Week High 56.67
Last Price 44.56
Fibonacci 61.8% 44.04
Fibonacci 50% 40.14
Fibonacci 38.2% 36.24
52-Week Low 23.61

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar